Email Alert | RSS    帮助

中国防痨杂志 ›› 2015, Vol. 37 ›› Issue (2): 167-172.doi: 10.3969/j.issn.1000-6621.2015.02.010

• 论著 • 上一篇    下一篇

抗结核药物治疗所致肝损伤的危险因素及其治疗转归分析

朱薇珊 张斌   

  1. 201700 复旦大学附属上海市中山医院青浦分院感染科
  • 收稿日期:2014-07-20 出版日期:2015-02-10 发布日期:2015-03-21
  • 通信作者: 张斌 E-mail:zhxy2010@163.com

Preliminary clinical study on the related factors in drug-induced liver injury of anti-TB patients

ZHU Wei-shan, ZHANG Bin   

  1. Department of Infection Disease of  Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China
  • Received:2014-07-20 Online:2015-02-10 Published:2015-03-21
  • Contact: ZHANG Bin E-mail:zhxy2010@163.com

摘要: 目的 探讨抗结核治疗导致药物性肝损伤患者相关危险因素及临床特点。 方法 回顾性分析复旦大学附属上海市中山医院青浦分院感染科2009年1月1日至2012年12月30日期间721例初治肺结核患者接受抗结核治疗后导致药物性肝损伤的发生情况,并对其肝病既往史、年龄、性别、痰结核分枝杆菌、酗酒及营养不良等相关危险因素进行研究,并比较有无肝病既往史在临床症状、肝损伤程度、出现异常时间及其对抗结核疗程疗效的影响。采用SPSS 11.0软件进行分析,计数资料的统计采用卡方检验,统计采用样本率比较,多因素采用logistic回归分析,P<0.05为差异有统计学意义。 结果 抗结核治疗后出现药物性肝损伤共99例,占13.7%(99/721)。单因素分析显示,既往肝病史[27.5%(39/142)和10.4%(60/579);χ2=28.16,P<0.01];年龄[25~岁组:8.0%(25/311),40~岁组:9.7%(24/248),60~70岁组:30.9%(50/162);χ2=28.44,P<0.01];酗酒[(29.7%(11/37)和12.9%(88/684);χ2=8.43,P<0.01];营养不良[19.1%(60/314)和9.6%(39/407);χ2=13.58,P<0.01]。多因素分析显示,既往肝病史(Waldχ2=22.994,P<0.01,OR=3.272,95%CI:2.016~5.312)、酗酒(Waldχ2=5.390,P<0.05,OR=2.667,95%CI:1.165~6.103)、年龄(Waldχ2=21.187,P<0.01,OR=2.010,95%CI:1.493~2.706)和营养不良(Waldχ2=4.563,P<0.05,OR=1.692,95%CI:1.044~2.742)是发生药物性肝损伤的相关危险因素。另外,既往肝病史的患者发生药物性肝损伤后肝损伤恢复时间[24.2%(15/62)和64.9%(24/37),χ2=16.054,P<0.01]、化疗方案更改[28.6%(16/56)和53.5%(23/43),χ2=6.325,P<0.05]较没有既往肝病史的患者差异有统计学意义。 结论 有肝病既往史、老年人、酗酒及营养不良是造成抗结核药物性肝损伤的危险因素,抗结核治疗方案需要根据病情做及时调整,以顺利完成化疗。

关键词: 结核, 肺/药物疗法, 抗结核药, 药物性肝损伤, 危险因素

Abstract: Objective To explore the related factors and clinical characteristics of liver injury in anti-TB patients. Methods The incidence of liver injury in 721 new tuberculosis (TB) cases received treatment from January 1, 2009 to December 30, 2012 in the Department of Infection Disease of Qingpu Branch of Zhongshan Hospital was calculated, the history of liver diseases, age, gender, status of sputum Mycobacterium tuberculosis, history of alcoho-lism, malnutrition, and other related factors were studied and the clinical symptoms, liver damage degree, time of abnormal with/without history of liver diseases were compared and the influences to anti-TB treatment were analyzed as well. SPSS 11.0 was used for data analysis. Theχ2 test and logistic method were used in the comparison of categorical variables, P<0.05 was considered statistically significant.  Results Ninety-nine cases of drug-induced liver injury were diagnosed in 721 patients, accounting for 13.7% (99/721). History of liver diseases (27.5% (39/142) vs 10.4% (60/579), χ2=28.16, P<0.01), age (25- age group: 8.0% (25/311), 40- age group: 9.7% (24/248), 60-70 age group: 30.9% (50/162); χ2=28.44, P<0.01), alcohol abuse (29.7% (11/37) vs 12.9% (88/684), χ2=8.43, P<0.01) and malnutrition (19.1% (60/314) vs 9.6% (39/407), χ2=13.58, P<0.01) were risk factors by univariate analysis. History of liver diseases (Waldχ2=22.994, P<0.01, OR=3.272, 95%CI: 2.016-5.312), alcohol abuse (Waldχ2=5.390, P<0.05, OR=2.667, 95%CI: 1.165-6.103), elderly (Waldχ2=21.187, P<0.01, OR=2.010, 95%CI: 1.493-2.706) and malnutrition (Waldχ2=4.563, P<0.05, OR=1.692, 95%CI: 1.044-2.742)were more likely to suffer drug-induced liver injury by multivariate analysis. It took longer to recover from liver injury induced by anti-TB drugs for the patients with liver diseases history (24.2% (15/62) vs 64.9% (24/37), χ2=16.054, P<0.01). On the basis of protecting liver treatment, we had to adjust the plan and prolong the chemotherapy compared to the patients without liver diseases history (28.6% (16/56) vs 53.5% (23/43), χ2=6.325, P<0.05). Conclusion History of liver diseases, the elderly, alcohol abuse and malnutrition are risk factors for TB drug-induced liver injury. It is necessary to monitor the liver function closely and adjust the anti-TB treatment regimen timely in order to complete the chemotherapy smoothly.

Key words: Tuberculosis, pulmonary/drug therapy, Antitubercular Agents, Drug-induced liver injury, Risk factors